Highlights Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 14/05/2024 pm IST			5-day change	1st Jan Change
1.2 ^HKD	+9.09%		+13.21%	-26.38%

22/04	Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	CI
22/04	Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	22/04	CI
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	22/04	MT
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	01/02	CI
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	27/11	CI
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11/23/11	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	22/23/22	CI
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826	19/23/19	CI
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	11/23/11	CI
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China	08/23/08	CI
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of AR-PROTAC (GT20029 ) for Treatment of Men Androgenetic Alopecia in China	14/23/14	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China	28/23/28	CI
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia and Acne Presented at AAD 2023	21/23/21	CI
Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound	10/23/10	CI
Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met	01/22/01	CI
Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China	24/22/24	CI
Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S	27/22/27	CI
Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China	16/22/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Highlights

Filters